Home › NCT06804980
DESIFOR-EXPAND (MHIF)
RecruitingPhase 4
The DEterminig Statin Intolerance for Rosuvastatin Trial
Who can join
Ages 21 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Adult patients (≥ 21 years old) with a prior history of statin intolerance. Statin intolerance is defined by discontinuation of at least 2 different statin medications due to possible side effects. Patients can participate in the trial while on other lipid-lowering agents, such as ezetimibe and PSCK9 inhibitors, as long as the patient has been on the other lipid lowering therapy and tolerating it well for at least 1 month. For individuals with established ASCVD or multiple ASCVD risk factors, initiation of other lipid lowering therapy prior to participation in DESIFOR is encouraged. * 2\. At least 30 days since discontinued use of a statin Exclusion Criteria: * Women who are pregnant, nursing or attempting to become pregnant * Individuals who experienced severe reactions in the past, including rhabdomyolysis, severe myositis, anaphylaxis * Individuals who are not otherwise clinically indicated to take rosuvastatin 20 mg
About the study
The DESIFOR pilot study was conducted to determine the feasibility of utilizing an n-of-1 trial to facilitate tolerance of unblinded rosuvastatin in patients with prior statin intolerance
What is being tested
- Rosuvastatin (Crestor) (drug)
- Placebo (drug)
Sponsor: Minneapolis Heart Institute Foundation · Participants: 100 · Started: Feb 1, 2025
Contact the study team
- Gretchen Program Director, RDN, CDCES · Phone: 612-863-3383
Official record on ClinicalTrials.gov — NCT06804980
Locations in the U.S.
| Minnesota | Minneapolis Heart Institute Foundation, Minneapolis |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.